The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Firazyr 30 mg solution for injection in pre-filled syringe



Takeda Pharmaceuticals International AG Ireland BranchEU/1/08/461/001-002

Main Information

Trade NameFirazyr 30 mg solution for injection in pre-filled syringe
Active SubstancesIcatibant
Dosage FormSolution for injection in pre-filled syringe
Licence HolderTakeda Pharmaceuticals International AG Ireland Branch
Licence NumberEU/1/08/461/001-002

Group Information

ATC CodeB06AC Drugs used in hereditary angioedema
B06AC02 icatibant

Status

License statusAuthorised
Licence Issued11/07/2008
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Generics Information

Interchangeable List CodeIC0148-033-063
Interchangeable List DocumentPDF of Interchangeable List
« Back